ILOSONE LIQUID 250MG/5ML DIN 00210641
Status: Cancelled Post Market
Holder: ELI LILLY CANADA INC
Molecule: ERYTHROMYCIN (ERYTHROMYCIN ESTOLATE)
Health Canada record
| Active ingredient(s) | ERYTHROMYCIN (ERYTHROMYCIN ESTOLATE) 250 MG |
|---|---|
| Dosage form | Suspension |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01FA01 ERYTHROMYCIN |
| Original market date | 31-Dec-1972 |
| Current status date | 03-Aug-2000 |
| Source | Health Canada DPD |
Establishment licence of the holder
Eli Lilly Canada Inc. — licence 100164, currently licensed, last inspection rating C (2026-03-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ERYTHROMYCIN (ERYTHROMYCIN ESTOLATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00015202 | ILOSONE 250MG PULVULE 375 | ELI LILLY CANADA INC | Capsule | ERYTHROMYCIN (ERYTHROMYCIN ESTOLATE) 250 MG | Cancelled Post Market |
| 00015474 | ILOSONE LIQUID 125MG/5ML | ELI LILLY CANADA INC | Suspension | ERYTHROMYCIN (ERYTHROMYCIN ESTOLATE) 125 MG | Cancelled Post Market |
| 00020966 | NOVO-RYTHRO ESTOLATE CAP 250MG | NOVOPHARM LIMITED | Capsule | ERYTHROMYCIN (ERYTHROMYCIN ESTOLATE) 250 MG | Cancelled Post Market |
| 00021172 | NOVO-RYTHRO ESTOLATE SUSPENSION | TEVA CANADA LIMITED | Suspension | ERYTHROMYCIN (ERYTHROMYCIN ESTOLATE) 125 MG | Cancelled Post Market |
| 00262595 | NOVO-RYTHRO ESTOLATE SUSPENSION | TEVA CANADA LIMITED | Suspension | ERYTHROMYCIN (ERYTHROMYCIN ESTOLATE) 250 MG | Cancelled Post Market |